Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
9 evidence topics · 8 sources
Upper airway collapse when anatomical collapsing forces exceed dilator muscle compensation
Endotype framework: four physiological traits that cause OSA
“In this study, we present a noninvasive method for measuring four important physiological traits causing OSA: 1) pharyngeal anatomy/collapsibility, 2) ventilatory control system gain (loop gain), 3) the ability of the upper airway to dilate/stiffen in response to an increase in ventilatory drive, and 4) arousal threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The measurements and model illustrate the multifactorial nature of OSA pathogenesis and how, in some individuals, small adjustments of one or another trait (which might be achievable with non-CPAP agents) could potentially treat OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endotype framework: distribution of anatomical and nonanatomical traits among patients with OSA
“A total of 36% of patients with OSA had minimal genioglossus muscle responsiveness during sleep, 37% had a low arousal threshold, and 36% had high loop gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 28% had multiple nonanatomic features.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One or more nonanatomic pathophysiologic traits are present in 69% of patients with OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study confirms that OSA is a heterogeneous disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endotype framework: impaired anatomy and the three nonanatomical phenotypes
“Indeed, impairment in pharyngeal anatomy can be modest and in many patients (∼20%), pharyngeal collapsibility asleep is not different to people without OSA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These include impairment in pharyngeal dilator muscle control and function during sleep, increased propensity for awakening during airway narrowing (low respiratory arousal threshold) and respiratory control instability (high loop gain).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Each phenotype is a potential therapeutic target.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endotype framework: estimating collapsibility and muscle compensation from diagnostic polysomnography
“Here we aimed to provide a means to quantify two key contributors to OSA—pharyngeal collapsibility and compensatory muscle responsiveness—that is applicable to diagnostic polysomnography.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Phenotypes of pharyngeal dysfunction in OSA are evident from spontaneous changes in ventilation and ventilatory drive during sleep, enabling noninvasive phenotyping in the clinic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: noradrenergic withdrawal in NREM sleep and muscarinic inhibition in REM sleep
“Some preclinical works identified the main cause of sleep-related hypotonia of the pharyngeal muscles to be the central reduction of norepinephrine from wakefulness to sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, an inhibitory effect of acetylcholine through muscarinic receptors was found to be responsible for the REM-related hypotonia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two key contributors are now thought to be important: sleep-related withdrawal of endogenous noradrenergic drive is a major cause of genioglossus hypotonia, particularly during non-REM (NREM) sleep (16), and active muscarinic inhibition mediates pharyngeal hypotonia, particularly during REM (17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: muscarinic and GIRK channel inhibition at the hypoglossal motor pool in REM sleep (rat study)
“Here we show that muscarinic receptor antagonism at the hypoglossal motor pool prevents the inhibition of genioglossus activity throughout REM sleep; likewise, with G-protein-coupled inwardly rectifying potassium (GIRK) channel blockade.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This mechanism is the major cause of REM sleep inhibition at a pharyngeal motor pool critical for effective breathing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: genioglossus motor unit activity during REM sleep in humans
“Overall these data show diminished genioglossus activity during REM (particularly phasic REM) as evidenced by fewer SMUs being active, reduced discharge frequencies, and shorter firing durations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neither the source of this cholinergic input nor the nature of interactions between cholinergic, noradrenergic, and other excitatory neurochemicals is understood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: hypoglossal motor nucleus mechanisms targeted by AD109 (review; one author is an Apnimed employee)
“While anatomical vulnerability contributes to airway instability, a key determinant of OSA pathophysiology is the sleep-related reduction in upper airway neuromuscular activity that occurs at the wake–sleep transition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonanatomical causes contribute to OSA in approximately 70% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This endogenous noradrenergic excitation at the HMN is present in wakefulness, reduced in non-REM (NREM) sleep, and further reduced in REM sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upper airway dilator muscle activity decreases during sleep due to withdrawal of excitatory drive, including noradrenergic input, in rapid eye movement (REM) and non-REM (NREM) sleep, and recruitment of inhibitory muscarinic–GIRK (G-protein–coupled inwardly rectifying potassium) mechanisms in REM sleep at upper airway motor nuclei.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“R.L.H.’s laboratory received an unrestricted grant in September 2024 from Apnimed, Inc. to support future research in obstructive sleep apnea (OSA) pharmacotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“L.T.-M. is an Apnimed employee and is co-inventor of intellectual property for pharmacological therapy of OSA via the Brigham and Women’s Hospital.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote